期刊文献+

BMP-2表达上调剂的筛选及其抗骨质疏松活性研究 被引量:5

Identification and anti-osteoprosis activity research of up-regulators of bone morphogenetic protein-2
下载PDF
导出
摘要 目的筛选上调骨形态发生蛋白2(BMP-2)表达的新型小分子活性化合物,为研发抗骨质疏松药物提供先导化合物。方法应用国家新药(微生物)筛选实验室前期建立的BMP-2表达上调剂的高通量筛选模型,对化合物库中10000余个化合物进行筛选,以染料木素作为阳性对照;应用实时定量 PCR 和 Western blot 方法检测活性化合物对 U-2OS 细胞 BMP-2 mRNA 和蛋白表达水平的影响。在mRNA 水平考察了活性化合物对 Runx2表达的影响, Western blot 法检测活性化合物对 Smad1/5/8蛋白磷酸化水平的影响;用 PNPP 法检测碱性磷酸酶活性,验证活性化合物体外促进成骨细胞分化的作用。结果在 BMP-2表达上调剂模型细胞上筛选得到活性化合物 E19773,其在模型细胞上的 EC50为46.2μmol/L;实时定量 PCR 结果显示,化合物 E19773能够提高 U-2OS细胞 BMP-2和 Runx2的 mRNA 表达水平;Western blot结果显示,Smad1/5/8蛋白磷酸化水平明显升高;碱性磷酸酶结果表明 E19773能够在体外促进成骨细胞的分化。结论化合物 E19773在0.75~50μmol/L 浓度范围内能明显上调 BMP-2的表达,主要通过 Smads 通路来调控细胞成骨分化,是活性较好的 BMP-2上调剂。 Objective To discover potential small-molecular compounds with the anti-osteoporosis functions by up-regulating the expression of bone morphogenetic protein-2 (BMP-2). Methods The process of screening was performed using a cell-based high-throughput screening model for BMP-2 with genistein as a positive control. Runx2 is a major osteogenic transcription factor in BMP-2-mediated pathway, and Smad1/5/8 is a very important signaling molecule in this pathway. The mRNA and protein expression levels of BMP-2, Runx2 and Smad1/5/8 phosphorylation were measured by real time PCR and Western blot, respectively. The activity of ALP was measured by the method of PNPP. Results Compound E19773 with the activity of up-regulating the expression of BMP-2 was found by PMB models, and the EC50 value of E19773 was 46.2μmol/L. E19773 was found to significantly increase the mRNA expression levels of BMP-2 and Runx2, as well as increase the protein expression levels of BMP-2, Runx2 and Smad1/5/8 phosphorylation in U-2OS cells. In vitro results of ALP activity indicated that E19773 was able to promote osteoblast differentiation. Conclusion Compound of E19773 can up-regulate the expression of BMP-2 through BMP-Smad pathway at the concentration of 0.75-50μmol/L. Thus the compound can be regarded as a lead compound for the development of new drugs to prevent and treat osteoporosis in the future.
出处 《中国医药生物技术》 2015年第3期236-241,共6页 Chinese Medicinal Biotechnology
关键词 骨质疏松 高通量筛选 骨形态发生蛋 白质2 Osteoporosis High-throughput screening Bone morphogenetic protein 2
  • 相关文献

参考文献14

二级参考文献81

  • 1马慧萍,贾正平,葛欣,陈克明.骨质疏松症的药物防治研究现状[J].中国药师,2004,7(10):816-818. 被引量:14
  • 2[1]Urist M R. Bone formation by autoinduction[J]. Science, 1965,150(698):893-899. 被引量:1
  • 3[2]Mizutani H, Urist M R. The nature of bone morphogenetic protein (BMP) fractions derived from bovine bone matrix gelatin[J]. Clin Orthop,1982,171(11):213-223. 被引量:1
  • 4[3]Peter S J, Lu L, Kim D J, et al. Marrow stromal osteoblast function on a poly (propylene fumarate)/β-tricalcium phosphate biodegradable orthopaedic composite[J]. Biomaterials,2000,21(12):1 207-1 213. 被引量:1
  • 5[4]Urist M R, Kovacs S, Yates K A. Regeneration of an enchondroma defect under the influence of an implant of human bone morphogenetic protein[J].J Hand Surg (Am),1986,11(3):417-419. 被引量:1
  • 6[5]Johnson E E, Urist M R, Finerman G A. Bone morphogenetic protein augmentation grafting of resistant femoral nonunions: a preliminary report[J]. Clin Orthop,1988,230(5):257-265. 被引量:1
  • 7[6]Prockop D J. Marrow stromal cells as stem cells for nonhematopoietic tissue[J]. Science,1997,276(4):71-74. 被引量:1
  • 8[7]Petite H, Viateau V, Bensaid W, et al. Tissue-engineered bone regeneration[J]. Nat Biotech,2000,18(9):959-963. 被引量:1
  • 9Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis: a system artic-review. CMAJ, 2006,175(1):52-59. 被引量:1
  • 10Horwitz MJ, Tedesco MB, Gundberg C, et al. Short-term, highdose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.J Clin Endocrinol Metab, 2003,88(2):569-575. 被引量:1

共引文献42

同被引文献54

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部